| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_791baadefaa50957824d2e8037478adf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8c00d33a47e00d9f505d9f66861b356
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7cd63f84867b8a2171f0e803ddde588
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdc86ab02f7f718eb957461ccea3516d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60e73403ebcc6800e0ebb865a71a36be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbdae795137f6a200d897d4cbffc65fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b09f545ba7cde938b86fbbee05b1b441 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2012-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ce788bfc1cd0f3f5b3128c3aacc03b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed15657b59285dbc1373551ac83b40d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d92a7ad5fa00cfc88e8f6cd9128e346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2311d27603234cbe3a2dcbffa90ad919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_844fa9fb76aee1e75817572d03c55097
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab1cbd94de8243348be94e4cf723c2f0 |
| publicationDate |
2014-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8697079-B2 |
| titleOfInvention |
IgE antibodies for the treatment of cancer |
| abstract |
The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018144425-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10908168-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11709167-B2 |
| priorityDate |
2008-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |